Tecom embarks on its next phase of growth
The Indian rupee was little changed on Tuesday after surrendering its opening gains due to the dollar demand from corporates, traders said.
The rupee was at 22.51 against the UAE dirham by 9.16am UAE time, barely changed from the previous session. The currency had inched up to 22.50 at the open.
[Editor's Note: For real-time forex rates, click the widget below or visit KT's dedicated Trading News page here.]
"The big corporates (who are importers) are quite active on the dips (on USD/INR), which, in the current context, makes sense," a forex salesperson at a private bank said.
"Then there is the usual (dollar) demand that we see at this time of the month."
The rupee reached 22.44 (against UAE Dirham) last Thursday but has struggled since due to the demand from importers.
Anil Bhansali, head of treasury at advisory firm Finrex Treasury Advisors, said he is telling his importer clients to buy the dips on the USD/INR.
Other Asian currencies rose between 0.1 per cent and 0.4 per cent, helped by the dollar index's drop to 103.82 and the dip in US Treasury yields. The 2-year yield fell to 4.99 per cent.
A healthy risk appetite helped. China equities continued to rally after Beijing, over the weekend, introduced a package of measures to boost markets.
Investors' focus now turns to the slew of US data due later this week, which will help them assess how the economy is faring and gauge the outlook for interest rates.
Federal Reserve Chair Jerome Powell was more hawkish at Jackson Hole last Friday than he was in July, prompting investors to raise the odds of one more rate hike this year.
ALSO READ:
Tecom embarks on its next phase of growth
Loyalty schemes, AI and customer retention will be key
Transaction value expected to hit $29.75 billion this year
Overall volume of digital payments in Mena has grown nearly seven-fold since 2020
In 2023, total consumption of gold in the UAE reached 39.7 tonnes
Maritime India Vision 2030 envisions investment of Rs1.25 trillion
Profitability, cash flow and capital expenditure guidance reiterated
Swiss pharma firm has an annual capacity of 250 million tablets